Eplontersen vs Patisiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Transthyretin Amyloidosis with Polyneuropathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline
Eplontersen · Wainua
Marketed by AstraZeneca and partners
NCT04136184 · Phase 3 · completed
This open-label Phase 3 trial randomized 168 people with hereditary transthyretin amyloid polyneuropathy 6:1 to eplontersen or inotersen, but the primary efficacy comparisons were made between the eplontersen group and an external placebo group from an earlier, separate trial (NEURO-TTR). At Week 66 eplontersen was favored on neuropathy impairment (mNIS+7, LS mean difference -24.76, 95% CI -30.96 to -18.56) and on Norfolk quality of life (-19.74, 95% CI -25.63 to -13.84), and serum TTR fell by 70.42 percentage points more at Week 65, all with p<0.0001. Because the comparison group was neither randomized nor treated within this study, and no one was blinded, these results are more open to bias than a concurrent placebo-controlled comparison.
No aligned efficacy figure on record for this race.
Patisiran · ONPATTRO
Marketed by Alnylam Pharmaceuticals
NCT01960348 · Phase 3 · completed
In this randomized, double-blind, placebo-controlled phase 3 trial, 225 participants received patisiran (148) or placebo (77). The hard clinical primary endpoint, change in mNIS+7 at 18 months, favored patisiran and was statistically significant: -6.03 versus 27.96 points, a between-group difference of -33.99 (p<0.0000001).
Reported efficacy
Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) (met)
Result source: NCT01960348
Results for Transthyretin Amyloidosis with Polyneuropathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Eplontersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eplontersen's landscape · Patisiran's landscape